Eterna Therapeutics Announces $9.2M Convertible Debt And Warrant Financing
Eterna Therapeutics Announces $9.2M Convertible Debt And Warrant Financing
Eterna Therapeutics Inc. a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it expects to receive proceeds of approximately $7.8 million on December 15, 2023 and the remainder at a closing to occur no later than January 15, 2023.
致力於發掘mRNA細胞工程爲患者提供變革性新藥的潛力的生命科學公司Eterna Therapeutics Inc. 今天宣佈與合格投資者簽訂證券購買協議，出售本金總額約920萬美元的優先可轉換期票和隨附的認股權證，通過根據納斯達克規則在市場上定價的私募交易中購買總計9,579,014股普通股。該公司預計將在2023年12月15日舉行首次收盤，預計將在2023年12月15日收到約780萬美元的收益，其餘款項將在不遲於2023年1月15日收盤時收到。